F3/F4纤维化患者获得SVR后的HCC监测
该文讨论丙型肝炎病毒清除后肝细胞癌(HCC)风险持续存在,F3/F4纤维化患者需长期监测;肝硬化患者应无限期监测,无明确肝硬化但风险足够高者也可能需监测。文章强调用简化评分、弹性成像和多变量风险计算器估算HCC风险以指导个体化监测。
要点
- F4肝硬化患者获得SVR后仍应无限期监测HCC。
- 无明确肝硬化但HCC风险足够高者,SVR后也可能需监测。
- 可用FIB-4、弹性成像或多变量计算器估算HCC风险。
核心结论
- 丙肝抗病毒治疗清除病毒可降低但不能消除HCC风险。
- 已确诊肝硬化者获得SVR后应无限期监测HCC。
- 未来可基于风险分层实施个体化精准HCC筛查。
主要发现
- 已确诊肝硬化患者在SVR多年后仍可能具有高HCC风险。
- 无明确或已知肝硬化者若HCC风险足够高,SVR后仍可能需要监测。
- 简化评分系统、肝脏弹性成像和多变量HCC风险计算器是估算HCC风险的有前景策略。
关键数值与推荐
- 已确诊肝硬化患者获得SVR后需无限期HCC监测。
- 无明确肝硬化但HCC风险足够高者,获得SVR后可能仍需监测。
- HCC风险是决定是否及如何筛查HCC的最重要因素之一。
临床怎么用
- 对F3/F4纤维化获得SVR者应评估HCC风险并决定是否监测。
- 已确诊肝硬化者SVR后应持续无限期HCC监测。
- 可借助FIB-4、弹性成像或多变量计算器进行风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
HCV eradication by antiviral treatment reduces but does not eliminate HCC risk. Patients with established cirrhosis require HCC surveillance "indefinitely" after sustained virologic response (SVR) because they appear to have a high risk of HCC even many years after SVR. Patients without established or known cirrhosis may still require surveillance after SVR if they have a sufficiently high HCC risk. In all patients who achieve SVR, the key question is how we can reliably estimate HCC risk, and the change in HCC risk over time, to determine whether the patient might benefit from HCC surveillance. HCC risk is one of the most important factors that should inform decisions of whether and how to screen for HCC. Promising strategies for estimating HCC risk include simplified scoring systems (such as fibrosis-4), liver elastography and multivariable HCC risk calculators. Such tools may enable risk stratification and individualised, risk-based surveillance strategies ("precision HCC screening") in the future.
引用
- Ioannou GN. HCC surveillance after SVR in patients with F3/F4 fibrosis. J Hepatol. 2020. PMID: 33303216. doi:10.1016/j.jhep.2020.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。